Effects of endostar combined multidrug chemotherapy in osteosarcoma

Bone

Volumn 57, Issue 1, 2013, Pages 111-115

  Xu, Meng ^a   Xu, Cheng Xiong ^b   Bi, Wen Zhi ^a   Song, Zhi Gang ^a   Jia, Jin Peng ^a   Chai, Wei ^a   Zhang, Li Hai ^a   Wang, Yan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Combination treatment; Endostatin; Metastasis; Osteosarcoma

Indexed keywords

CD31 ANTIGEN; CISPLATIN; DOXORUBICIN; METHOTREXATE; RECOMBINANT ENDOSTATIN; VASCULOTROPIN;

ADOLESCENT; ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR LOCALIZATION;

ANGIOGENESIS; COMBINATION TREATMENT; ENDOSTATIN; METASTASIS; OSTEOSARCOMA;

ADOLESCENT; ADULT; ANTIGENS, CD31; CHILD; CHILD, PRESCHOOL; ENDOSTATINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84882772574     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.07.035     Document Type: Article

References (41)

1. Messerschmitt P.J., Garcia R.M., Abdul-Karim F.W., Greenfield E.M., Getty P.J. Osteosarcoma. J Am Acad Orthop Surg 2009, 17:515-527.
2. O'Day K., Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009, 9:511-523.
3. Chen Y., Yang Y., Yuan Z., Wang C., Shi Y. Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry. Oncol Lett 2012, 3:1011-1016.
4. Rosen G., Suwansirikul S., Kwon C., Tan C., Wu S.J., Beattie E.J., et al. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 1974, 33:1151-1163.
5. Bacci G., Longhi A., Fagioli F., Briccoli A., Versari M., Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27year experience at Rizzoli Institute, Italy. Eur J Cancer 2005, 41:2836-2845.
6. Allison D.C., Carney S.C., Ahlmann E.R., Hendifar A., Chawla S., Fedenko A., et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012:704872.
7. Xu H., Niu X., Zhang Q., Hao L., Ding Y., Liu W., et al. Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncol Lett 2011, 2:773-778.
8. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
9. Kim H.S., Lim S.J., Park Y.K. Anti-angiogenic factor endostatin in osteosarcoma. APMIS 2009, 117:716-723.
10. DuBois S.G., Marina N., Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 2010, 116:749-757.
11. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
12. Jia Y., Liu M., Huang W., Wang Z., He Y., Wu J., et al. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res 2012, 18:315-323.
13. Jia Y., Liu M., Cao L., Zhao X., Wu J., Lu F., et al. Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol 2011, 32:316-324.
14. Li N., Zheng D., Wei X., Jin Z., Zhang C., Li K. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol 2012, 138:1131-1144.
15. Liang Z., Wu J., Huang J., Tan W., Ke M., Liu R., et al. Bioactivity and stability analysis of endostatin purified from fermentation supernatant of 293 cells transfected with Ad/rhEndo. Protein Expr Purif 2007, 56:205-211.
16. Ke Q.H., Zhou S.Q., Huang M., Lei Y., Du W., Yang J.Y. Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev 2012, 13:923-926.
17. Zhou J.F., Bai C.M., Wang Y.Z., Li X.Y., Cheng Y.J., Chen S.C. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J (Engl) 2011, 124:4299-4303.
18. Li Y., Huang X.E., Yan P.W., Jiang Y., Xiang J. Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev 2010, 11:1119-1123.
19. Kulke M.H., Bergsland E.K., Ryan D.P., Enzinger P.C., Lynch T.J., Zhu A.X., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24:3555-3561.
20. Jiang X.D., Dai P., Wu J., Song D.A., Yu J.M. Effect of Recombinant Human Endostatin on Radiosensitivity in Patients With Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2012, 83:1272-1277.
21. Fu X.H., Li J., Zou Y., Hong Y.R., Fu Z.X., Huang J.J., et al. Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Lett 2011, 312:109-116.
22. Kaya M., Wada T., Nagoya S., Yamashita T. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci 2007, 12:562-567.
23. Ferrari S., Ruggieri P., Cefalo G., Tamburini A., Capanna R., Fagioli F., et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 2012, 30:2112-2118.
24. Rossi B., Schinzari G., Maccauro G., Scaramuzzo L., Signorelli D., Rosa M.A., et al. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord 2010, 11:34.
25. Del Vecchio M., Mortarini R., Canova S., Di Guardo L., Pimpinelli N., Sertoli M.R., et al. Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clin Cancer Res 2010, 16:5862-5872.
26. Yoon S.S., Duda D.G., Karl D.L., Kim T.M., Kambadakone A.R., Chen Y.L., et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2011, 81:1081-1090.
27. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999, 17:343-348.
28. Han B., Xiu Q., Wang H., Shen J., Gu A., Luo Y., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:1104-1109.
29. Sun Y., Wang J., Liu Y., Song X., Zhang Y., Li K., et al. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005, 23:654s.
30. Kaya M., Wada T., Nagoya S., Yamashita T. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci 2007, 12:562-567.
31. Strik H.M., Schluesener H.J., Seid K., Meyermann R., Deininger M.H. Localization of endostatin in rat and human gliomas. Cancer 2001, 91:1013-1019.
32. Mikulic D., Ilic I., Cepulic M., Orlic D., Giljevic J.S., Fattorini I., et al. Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol 2004, 21:611-619.
33. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003, 29:297-307.
34. Savitskaya Y.A., Rico-Martinez G., Linares-Gonzalez L.M., Delgado-Cedillo E.A., Tellez-Gastelum R., Alfaro-Rodriguez A.B., et al. Serum tumor markers in pediatric osteosarcoma: a summary review. Clin Sarcoma Res 2012, 2:9.
35. Kaya M., Wada T., Akatsuka T., Kawaguchi S., Nagoya S., Shindoh M., et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000, 6:572-577.
36. Kaya M., Wada T., Kawaguchi S., Nagoya S., Yamashita T., Abe Y., et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002, 86:864-869.
37. Tanaka T., Yui Y., Naka N., Wakamatsu T., Yoshioka K., Araki N., et al. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. Clin Exp Metastasis 2013, 30:369-379.
38. Wang X., Xu X., Tang L.S., Song S.P., Fan C.H. Interactions between endostatin and vascular endothelial growth factor (VEGF) and inhibition of choroidal neovascularization. Int J Mol Sci 2007, 8:61-69.
39. Kaya M., Wada T., Nagoya S., Kawaguchi S., Isu K., Yamashita T. Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J Bone Joint Surg Br 2004, 86:143-147.
40. Yamaguchi N., Anand-Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999, 18:4414-4423.
41. Enneking W.F., Spanier S.S., Goodman M.A. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 1980, 62:1027-1030.